Literature DB >> 8083829

Interaction of HIV-1 and human salivary mucins.

E J Bergey1, M I Cho, B M Blumberg, M L Hammarskjöld, D Rekosh, L G Epstein, M J Levine.   

Abstract

Previous studies have suggested that salivary secretions may act as inhibitors of HIV-1 replication in vitro. This inhibitory activity was determined to be associated mainly with secretions obtained from the human submandibular-sublingual glands, and subsequent electron micrographs revealed the association of viral particles with the salivary sediment. Fractionation of human submandibular-sublingual (HSMSL) saliva by size-exclusion chromatography was initiated, and resulting fractions were tested for their ability to modulate the replication of HIV-1 using a plaque assay on HeLa CD4+ cell monolayers. Results indicated that the filtration-sensitive inhibitory activity was primarily associated with the mucin-rich fractions, and the inhibitory activity was found to reduce the number of infectious units by 75%. To determine the identity of the salivary components involved, adsorption experiments involving the interaction of HIV particles with immobilized salivary components were performed. Immunological counter staining revealed an interaction of HIV particles as well as recombinant gp120 with the lower-molecular-weight mucin. Electron microscopic examination of the mucin-rich fractions-HIV incubates revealed the aggregation of virus particles by salivary components. These results suggest that human salivary mucins may have a role in modulating the infectivity of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083829

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  21 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

2.  Δ20 IFITM2 differentially restricts X4 and R5 HIV-1.

Authors:  Wan-Lin Wu; Christopher Robert Grotefend; Ming-Ting Tsai; Yi-Ling Wang; Vladimir Radic; Hyungjin Eoh; I-Chueh Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

3.  Mucin biopolymers as broad-spectrum antiviral agents.

Authors:  Oliver Lieleg; Corinna Lieleg; Jesse Bloom; Christopher B Buck; Katharina Ribbeck
Journal:  Biomacromolecules       Date:  2012-05-21       Impact factor: 6.988

4.  Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.

Authors:  S M Wahl; P Worley; W Jin; T B McNeely; S Eisenberg; C Fasching; J M Orenstein; E N Janoff
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

Review 5.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

6.  Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Paul Roux; Anwar S Mall
Journal:  Virol J       Date:  2010-10-14       Impact factor: 4.099

Review 7.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

Review 8.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles.

Authors:  J D Fontenot; V R Zacharopoulos; D M Phillips
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals.

Authors:  Nawei Zhang; Zhenyu Zhang; Shan Feng; Qingtao Wang; Daniel Malamud; Haiteng Deng
Journal:  Anal Chim Acta       Date:  2013-03-01       Impact factor: 6.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.